Efficacy and safety of lenvatinib and everolimus combination in patients with metastatic renal cell carcinoma progression following targeted antiangiogenic therapy: secondary analysis of data obtained in the Russian multicenter observational study
Authors: Volkova M. I. , Kalpinskiy A. S. , Borisov P. S. , Evsyukova O. I. , Olshanskaya A. S. , Matveev V. B. , Alekseev B. Ya. , Peganova E. V. , Nasretdinov A. F. , Lymar E. V. , Ovchinnikova E. G. , Sveklina T. A. , Usynin E. A. , Abdelgafur A. M. , Tararova E. A. , Shumova L. M. , Belenkov A. S. , Dolgov I. Yu. , Ponomareva N. G. , Evstigneeva I. V. , Ivanov A. N. , Isaev A. R. , Leonenkov R. V. , Meskikh A. V. , Mukhitova M. R. , Orlova S. A. , Teslenok I. V. , Shegurova M. M. , Aivazov M. T. , Amoev Z. V. , Babina K. G. , Vorontsova A. A. , Karabina E. V. , Kirdakova N. V. , Shumskaya I. E. , Kolesnikov G. P. , Kuzmina E. S. , Latipova D. Kh. , Lyutova E. S. , Fael M. M. , Chugarova A. N , Antipin A. S. 
Published: May 2021

Objective. The primary endpoint was progression-free survival; secondary endpoints included overall survival, objective response rate and duration, tumor control rate and duration, as well as safety profile of lenvatinib with everolimus in consecutive patients with advanced renal cell carcinoma who had disease progression after targeted antiangiogenic therapy.Materials and methods. This observational study included 129 consecutive patients with metastatic renal cell carcinoma resistant to targeted antiangiogenic therapy. The median age was 60 years; a male to female ratio was 3.1:1. Twenty-seven patients (20.9 %) had ECOG performance status of 2—4. The majority of study participants (n = 127; 98.4 %) had multiple metastases. Tumor lesions were located in >1 organ in 104 cases (80.6 %). The primary tumor was removed in 110 (85.3 %), including 39 (30.2 %) patients undergone cytoreductive surgery. Seventy patients (54.2 %) had earlier received more than one line of therapy. Upon enrollment, there were 13 IMDC favourable-risk patients (10.1 %), 86 IMDC intermediate-risk patients (66.6 %), and 29 IMDC poor-risk patients (22.5 %). In one patient (0.8 %), the IMDC risk was not estimated. All patients received lenvatinib at a dose of 18 mg/day and everolimus at a dose of 5 mg/day. The median follow-up was 10.5 (1—30) months.Results. Median progression-free survival was 14.9 (11.9—17.9) months; overall survival was 19.9 (15.2—24.6) months. The objective response rate was 17.0 % (median duration 9.7 (2.8—16.5) months); tumor control rate was 72.9 % (median duration 10.0 (2.5—17.5) months). Adverse events were observed in 112patients (86.8 %) with grade III—IVadverse events registered in 27participants (20.9 %). Five participants (3.9 %) needed inpatient treatment of adverse events; one patient (0.8 %) died due to adverse events. Adverse events required treatment discontinuation in 4 patients (3.1 %), treatment interruption in 35 patients (27.1 %), and dose reduction in 33 patients (25.6 %).Conclusion. The results of the secondary analysis in the ROSLERCM observational study confirmed the results obtained earlier on the efficacy and safety of the lenvatinib plus everolimus combination in the second- and subsequent-line therapy for advanced renal cell carcinoma resistant to targeted antiangiogenic therapy in consecutive Russian patients.